Overview

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole

Status:
Not yet recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
The study will assess the effect of multiple doses of itraconazole, a strong CYP3A4/5 inhibitor, on the PK of ganaplacide and lumefantrine in healthy participants. This study will provide data that is relevant for advice regarding possible concomitant medications that are inhibitors of CYP3A4/5 in future clinical studies with ganaplacide and lumefantrine and for potential future labeling considerations
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Medicines for Malaria Venture
Treatments:
Itraconazole
Lumefantrine